🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  2. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  3. Lipotecan

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  4. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  5. Low Dose MSH2-/- tumor cell vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    pMMR/MSS Advanced Colorectal Cancer

    phase 1 mab active

    1 trial

  6. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  7. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  8. M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  9. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  10. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  11. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  12. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  13. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  14. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  15. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  16. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  17. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  18. MTL-CEBPA

    Hospital Authority, Hong Kong

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  19. MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  20. Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  21. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. Minnelide™Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  23. NKTR-102

    Nektar Therapeutics UK Limited

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  24. NKTR-214

    Nektar Therapeutics UK Limited

    Advanced Cancer

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources